Ask AI
ProCE Banner Activity

Questions on Advances in Therapies for ADH1

Clinical Thought

Autosomal dominant hypocalcemia type 1 (ADH1) is a rare genetic disorder in which gain-of-function variants in the calcium-sensing receptor gene lead to hypoparathyroidism, hypocalcemia, and hypercalciuria. ADH1 has been treated using standard-of-care approaches for hypoparathyroidism, but more specific therapies are in development. Download this expert commentary to learn more about advances in ADH1 care.

Released: November 20, 2026

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education in partnership with HypoPARAthyroidism Association, Inc.

ProCE Banner

Supporters

This activity is supported by an independent educational grant from BridgeBio Pharma, Inc.

BridgeBio Pharma, Inc.

Partners

HypoPARAthyroidism Association, Inc

ProCE Banner

Target Audience

This activity is designed for clinicians involved in the management of patients with ADH1, including endocrinologists, nephrologists, primary care physicians, orthopedists, nurse practitioners, physician associates, and other members of the care team. 

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Evaluate emerging clinical trial evidence for novel therapeutic approaches that target the underlying causes of ADH1, including CaSR-targeted therapies, to optimize calcium homeostasis and reduce renal complications

Financial Disclosures

Primary Author

Michael Mannstadt, MD: consultant/advisor/researcher: Amolyt/Alexion, BridgeBio, MBX, Septerna, Takeda.